PCM
LUCD icon

Perkins Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Perkins Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29M Hold
1,126,000
– – 1.21% 22
2025
Q4 		$1.23M Sell
1,126,000
-1,000
-0.1% -$1.12K 0.97% 33
2025
Q3 		$1.14M Buy
+1,127,000
New +$1.23M 1% 33

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SS
Sunbelt Securities Houston, Texas $1.58B AUM 28.96% 1-Year Est. Return

Perkins Capital Management's LUCD Position: Q1 2026 in Review

Perkins Capital Management held its Lucid Diagnostics (LUCD) position steady in Q1 2026 at 1,126,000 shares worth $1.29M. The position accounts for 1.21% of the portfolio, ranked #22.

Perkins Capital Management first reported a position in LUCD in Q3 2025 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Perkins Capital Management held 1,126,000 shares of Lucid Diagnostics worth $1.29M as of Q1 2026.
  • Perkins Capital Management left its Lucid Diagnostics share count unchanged in Q1 2026.
  • Lucid Diagnostics made up 1.21% of Perkins Capital Management's portfolio in Q1 2026, its #22 holding.
  • Perkins Capital Management first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Perkins Capital Management's 13F filing for Q1 2026, filed 23 Apr 2026.